NCT03037437View on ClinicalTrials.gov

Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

February 16, 2017

Primary Completion Date

June 27, 2025

Study Completion Date

June 27, 2025

Conditions
Hepatocellular Cancer
Interventions
DRUG

Sorafenib (SOR)

Patients will receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1).

DRUG

Hydroxychloroquine (HCQ)

400mg by mouth daily

Trial Locations (1)

78229

University of Texas Health Cancer Center, San Antonio

All Listed Sponsors
lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT03037437 - Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer | Biotech Hunter | Biotech Hunter